Last reviewed · How we verify

CYD Dengue Vaccine Serotypes 1, 2, 3, and 4

Sanofi Pasteur, a Sanofi Company · Phase 2 active Biologic

CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 is a vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 2 development for Prevention of dengue fever caused by dengue virus serotypes 1, 2, 3, and 4. Also known as: ChimeriVax™.

The CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 is a tetravalent dengue vaccine that targets the envelope proteins of all four dengue virus serotypes to induce a protective immune response.

The CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 is a tetravalent dengue vaccine that targets the envelope proteins of all four dengue virus serotypes to induce a protective immune response. Used for Prevention of dengue fever caused by dengue virus serotypes 1, 2, 3, and 4.

At a glance

Generic nameCYD Dengue Vaccine Serotypes 1, 2, 3, and 4
Also known asChimeriVax™
SponsorSanofi Pasteur, a Sanofi Company
Drug classvaccine
TargetDengue virus envelope proteins (E proteins)
ModalityBiologic
Therapeutic areaInfectious Disease
PhasePhase 2

Mechanism of action

This vaccine works by presenting the immune system with antigens from all four dengue serotypes, stimulating the production of neutralizing antibodies and memory B cells, which can provide protection against future infections by any of the serotypes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about CYD Dengue Vaccine Serotypes 1, 2, 3, and 4

What is CYD Dengue Vaccine Serotypes 1, 2, 3, and 4?

CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 is a vaccine drug developed by Sanofi Pasteur, a Sanofi Company, indicated for Prevention of dengue fever caused by dengue virus serotypes 1, 2, 3, and 4.

How does CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 work?

The CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 is a tetravalent dengue vaccine that targets the envelope proteins of all four dengue virus serotypes to induce a protective immune response.

What is CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 used for?

CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 is indicated for Prevention of dengue fever caused by dengue virus serotypes 1, 2, 3, and 4.

Who makes CYD Dengue Vaccine Serotypes 1, 2, 3, and 4?

CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).

Is CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 also known as anything else?

CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 is also known as ChimeriVax™.

What drug class is CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 in?

CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 belongs to the vaccine class. See all vaccine drugs at /class/vaccine.

What development phase is CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 in?

CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 is in Phase 2.

What are the side effects of CYD Dengue Vaccine Serotypes 1, 2, 3, and 4?

Common side effects of CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 include Injection site pain, Headache, Fatigue.

What does CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 target?

CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 targets Dengue virus envelope proteins (E proteins) and is a vaccine.

Related